A phase II study of gemcitabine plus carboplatin in platinum-sensitive, recurrent ovarian carcinoma

Kose, MEHMET; Sufliarsky, J; Beslija, S; Saip, P; Tulunay, G; Krejcy, K; Minarik, T; Fitzthum, E; Hayden, A; Melemed, A

doi:10.1016/j.ygyno.2004.10.011

A phase II study of gemcitabine plus carboplatin in platinum-sensitive, recurrent ovarian carcinoma

Atıf İçin Kopyala

Kose M. F., Sufliarsky J., Beslija S., Saip P., Tulunay G., Krejcy K., ...Daha Fazla

GYNECOLOGIC ONCOLOGY, cilt.96, sa.2, ss.374-380, 2005 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 96 Sayı: 2
Basım Tarihi: 2005
Doi Numarası: 10.1016/j.ygyno.2004.10.011
Dergi Adı: GYNECOLOGIC ONCOLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.374-380
Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Hayır

Özet

Objectives. Gemcitabine and carboplatin each have demonstrated effectiveness without increased neurotoxicity in pretreated patients with ovarian cancer. We evaluated the efficacy and safety of gemcitabine plus carboplatin in patients with recurrent ovarian cancer in a multicenter phase II study.